Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 4;20(1):3.
doi: 10.1007/s11899-024-00748-5.

Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies

Praneeth Reddy Keesari  1 , Diana Samuels  2 , Charan Thej Reddy Vegivinti  3 , Yashwitha Sai Pulakurthi  4 , Revathi Kudithi  5 , Meekoo Dhar  6 , Murali Janakiram  7
Affiliations
Review

Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies

Praneeth Reddy Keesari et al. Curr Hematol Malig Rep. .

Abstract

Purpose of review: Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-effectiveness of therapies is crucial for clinicians and researchers.

Recent findings: In this, we review the recent approval of Bispecific antibodies and CAR-T for myeloma and their cost implications, including direct and indirect costs. We compare this to current regimens and provide cost comparisons in this review. We conclude that the use of more effective therapies such as CAR-T in earlier lines of therapies may be more cost-effective depending on the country and model used. Further studies are essential to better understand the cost-effectiveness of bispecific antibodies including head-to-head comparisons to CAR-T therapy.

Keywords: Bispecific antibodies; CAR-T; Cost-effectiveness; Economic; Multiple Myeloma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Disclosure: None.

Figures

Fig. 1
Fig. 1
Cost and Quality-Adjusted Life Years (QALY) Gained for Various Treatments in Multiple Myeloma: Comparisons Across Studies. Cilta-cel: Ciltacabtagene autoleucel, Ide-cel: Idecabtagene vicleucel, Standard Chemotherapy: Standard chemotherapy regimens as defined in the respective studies, Belantamab: Belantamab mafodotin, QALY gained: Quality adjusted life years gained
See this image and copyright information in PMC

References

    1. American Cancer Society. Key Statistics About Multiple Myeloma. American Cancer Society website. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statis-ti.... Published 2023. Accessed July 12, 2024.
    1. Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599–605. - PubMed
    1. Yang J, Boytsov N, Carlson JJ, Barthold D. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis. J Manag Care Spec Pharm. 2023;29(8):917–26. - PMC - PubMed
    1. Hollmann S, Moldaver D, Goyert N, Grima D, Maiese EM. A u. S. Cost analysis of triplet regimens for patients with previously treated multiple myeloma. J Manag Care Spec Pharm. 2019;25(4):449–59. - PMC - PubMed
    1. Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17(5):503–15. - PubMed

MeSH terms

Substances